Erik Russell Nelson

Erik Russell Nelson

Auto-generated profile, based on publicly available information

Erik Russell Nelson

Department of Molecular and Integrative Physiology, University of Illinois Urbana Champaign, Illinois, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2013 in Science
Verified
Journal Article
Closed access
PDF file
ENErik R. Nelson
Erik R. Nelson
SWSuzanne E. Wardell
Suzanne E. Wardell
JJJeff S. Jasper
Jeff S. Jasper
SPSunghee Park
Sunghee Park
SSSunil Suchindran
Sunil Suchindran
DMDonald P McDonnell
Donald P McDonnell
Cholesterol and Cancer: Obesity and high cholesterol levels are associated with an increased risk of breast cancer in post-menopausal women. Nelson et al. (p. 1094 ) found that a specific metabolite of cholesterol, 27-hydroxycholesterol (27HC), promoted tumor growth and metastasis in mouse models of mammary cancer by serving as a partial agonist for the estrogen receptor and the liver X receptor. The most aggressive human breast cancers were found to express the highest level of the enzyme that converts cholesterol to 27HC, suggesting that 27HC produced within tumors (in addition to circulating 27HC) may contribute to tumorigenesis.

11 October 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAmy E. Baek
Amy E. Baek
YYYen-Rei A. Yu
Yen-Rei A. Yu
SHSisi He
Sisi He
SWSuzanne E. Wardell
Suzanne E. Wardell
CCChing-Yi Chang
Ching-Yi Chang
ENErik R. Nelson
Erik R. Nelson
Obesity and elevated circulating cholesterol are risk factors for breast cancer recurrence, while the use of statins, cholesterol biosynthesis inhibitors widely used for treating hypercholesterolemia, is associated with improved disease-free survival. Here, we show that cholesterol mediates the metastatic effects of a high-fat diet via its oxysterol metabolite, 27-hydroxycholesterol. Ablation or inhibition of CYP27A1, the enzyme responsible for the rate-limiting step in 27-hydroxycholesterol biosynthesis, significantly reduces metastasis in relevant animal models of cancer. The robust effects of 27-hydroxycholesterol on metastasis requires myeloid immune cell function, and it was found that this oxysterol increases the number of polymorphonuclear-neutrophils and γδ-T cells at distal metastatic sites. The pro-metastatic actions of 27-hydroxycholesterol requires both polymorphonuclear-neutrophils and γδ-T cells, and 27-hydroxycholesterol treatment results in a decreased number of cytotoxic CD8+T lymphocytes. Therefore, through its actions on γδ-T cells and polymorphonuclear-neutrophils, 27-hydroxycholesterol functions as a biochemical mediator of the metastatic effects of hypercholesterolemia.

31 October 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
RMRyan D. Michalek
Ryan D. Michalek
VGValerie A. Gerriets
Valerie A. Gerriets
ANAmanda G. Nichols
Amanda G. Nichols
MIMakoto Inoue
Makoto Inoue
DKDmitri Kazmin
Dmitri Kazmin
JRJeffrey C. Rathmell
Jeffrey C. Rathmell
Stimulation of resting CD4 + T lymphocytes leads to rapid proliferation and differentiation into effector (Teff) or inducible regulatory (Treg) subsets with specific functions to promote or suppress immunity. Importantly, Teff and Treg use distinct metabolic programs to support subset specification, survival, and function. Here, we describe that the orphan nuclear receptor estrogen-related receptor-α (ERRα) regulates metabolic pathways critical for Teff. Resting CD4 + T cells expressed low levels of ERRα protein that increased on activation. ERRα deficiency reduced activated T-cell numbers in vivo and cytokine production in vitro but did not seem to modulate immunity through inhibition of activating signals or viability. Rather, ERRα broadly affected metabolic gene expression and glucose metabolism essential for Teff. In particular, up-regulation of Glut1 protein, glucose uptake, and mitochondrial processes were suppressed in activated ERRα −/− T cells and T cells treated with two chemically independent ERRα inhibitors or by shRNAi. Acute ERRα inhibition also blocked T-cell growth and proliferation. This defect appeared as a result of inadequate glucose metabolism, because provision of lipids, but not increased glucose uptake or pyruvate, rescued ATP levels and cell division. Additionally, we have shown that Treg requires lipid oxidation, whereas Teff uses glucose metabolism, and lipid addition selectively restored Treg—but not Teff—generation after acute ERRα inhibition. Furthermore, in vivo inhibition of ERRα reduced T-cell proliferation and Teff generation in both immunization and experimental autoimmune encephalomyelitis models. Thus, ERRα is a selective transcriptional regulator of Teff metabolism that may provide a metabolic means to modulate immunity.

1 October 2013 in General and Comparative Endocrinology
Verified
Journal Article
Closed access
ENErik R. Nelson
Erik R. Nelson
HHHamid R. Habibi
Hamid R. Habibi

14 October 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
RSRachid Safi
Rachid Safi
ENErik R. Nelson
Erik R. Nelson
SCSatish K. Chitneni
Satish K. Chitneni
KFKatherine J Franz
Katherine J Franz
DGDaniel J. George
Daniel J. George
DMDonald P McDonnell
Donald P McDonnell
Previously published reports indicate that serum copper levels are elevated in patients with prostate cancer and that increased copper uptake can be used as a means to image prostate tumors. It is unclear, however, to what extent copper is required for prostate cancer cell function as we observed only modest effects of chelation strategies on the growth of these cells in vitro. With the goal of exploiting prostate cancer cell proclivity for copper uptake, we developed a “conditional lethal” screen to identify compounds whose cytotoxic actions were manifested in a copper-dependent manner. Emerging from this screen was a series of dithiocarbamates, which, when complexed with copper, induced reactive oxygen species–dependent apoptosis of malignant, but not normal, prostate cells. One of the dithiocarbamates identified, disulfiram (DSF), is an FDA-approved drug that has previously yielded disappointing results in clinical trials in patients with recurrent prostate cancer. Similarly, in our studies, DSF alone had a minimal effect on the growth of prostate cancer tumors when propagated as xenografts. However, when DSF was coadministered with copper, a very dramatic inhibition of tumor growth in models of hormone-sensitive and of castrate-resistant disease was observed. Furthermore, we determined that prostate cancer cells express high levels of CTR1, the primary copper transporter, and additional chaperones that are required to maintain intracellular copper homeostasis. The expression levels of most of these proteins are increased further upon treatment of androgen receptor (AR)–positive prostate cancer cell lines with androgens. Not surprisingly, robust CTR1-dependent uptake of copper into prostate cancer cells was observed, an activity that was accentuated by activation of AR. Given these data linking AR to intracellular copper uptake, we believe that dithiocarbamate/copper complexes are likely to be effective for the treatment of patients with prostate cancer whose disease is resistant to classical androgen ablation therapies. Cancer Res; 74(20); 5819–31. ©2014 AACR.

1 December 2014 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
ENErik R. Nelson
Erik R. Nelson
CCChing-Yi Chang
Ching-Yi Chang
DMDonald P McDonnell
Donald P McDonnell